Professor Dr Thomas Schulz is based at Hannover Medical School (MHH) in the Institute of Virology and was the Head of the Institute until stepping down in 2024. Prof Schulz was the scientific coordinator of the DFG-funded Collaborative Research Centre on Chronic Infections and of the Cluster of Excellence ‘RESIST’ (‘Resolving Infection Susceptibility’). His research focus is the identification and validation of novel antiviral targets during the early stages of herpesvirus replication and the development of small molecular compounds that interfere with these targets. The long-term aim is to contribute to new treatment options for herpes disease, including combination therapies that utilize drugs acting at different stages of the viral life cycle. Prof Schulz is also the lead for the HAGIS (Hannover-Glasgow Infection Strategy) initiative.
